Light Dose Database

Researchers treated psoriasis patients without treating it with any photosensitizers. Protoporphyrin IX (PpIX) is an endogenous photoreceptor. Both 420 nm blue and 630 nm red equally reduced psoriasis symptoms. Blue reduced redness more than red.

Researchers combined topical curcumin with 405 nm blue light, and then either 630 nm or 660 nm red light. Both treatment groups showed significant decrease in symptoms. The treatments decreased keratinocytes cell proliferation, which is the primary causative factor in psoriasis symptoms.

Forty patients self-treated with 420 nm blue LED light therapy once a day for four weeks. 20 patients self-treated with 453 nm blue LED in parallel. Both groups should statistically substantial improvement at 4 weeks. Gains reversed when treatment stopped.

47 patients with mild psoriasis received 200 mW/cm^2 (group 1) or 100 mW/cm^2) group 2 UV-free blue LED treatment over 12 weeks. Patients reported high satisfaction with the results, which were statistically significant as well.

Nine psoriasis patients used 633 nm red and 830 nm infrared LED therapy on recalcitrant psoriasis. The majority had failed earlier treatments. Seven patients show 60% to 100% clearance of psoriasis symptoms when measured from three to 8 months after treatment. Two of the subjects could not be located.

Researchers treated 25 psoriasis patients with psoralen and ultraviolet-A (PUVA), and another 25 patients with psoralent and ultraviolet-B (PUVB). Psoriasis affected 25-70% of the patient’s skin. After 8 weeks of treatment, 92% of the PUVA group, and 80% of the PUVB group had remission. Limbs and trunk were more resistant than the rest of the body. 28% of PUVA and 24% of PUVB suffered erythema (redness); 32% and 28% pruitis (itchiness); 28% and 24% nausea and vomiting; 16% and 12% fever & malaise; 12% and 16% headache; 1% and 0% blister; 1% and 0% claustrophobia. Researchers concluded that PUVA and PUVB had substantially similar positive outcomes.

Physician’s office treatment (not a home therapy) using Narrow Band Ultraviolet B (NB-UVB) for psoriasis patients affected on greater than 10% of the body and have not responded to other treatments. UVB is dangerous without safety precautions. The doctor uses an excimer laser. The patient is treated 2x-3x per week. Is potentially combined with “emollients, calcipotriene, cortico-steroids, retinoids, and tar. NB-UVB can be used in selected patients with traditional systemic agents such as methotrexate, mycophenolate mofetil, and cyclosporine…”